A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)
Clinical trial NCT02953314 · COMPLETED
Trial details
- NCT number
- NCT02953314
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-01
- Primary completion
- 2018-09-01
- Enrollment
- 83
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.